IC
CYTK icon

Ikarian Capital’s Cytokinetics CYTK Stock Holding History

Ikarian Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-408,400
Closed -$26.9M – 163
2026
Q1 		$26.9M Buy
408,400
+117,500
+40% +$7.47M 2.19% 10
2025
Q4 		$18.5M Buy
290,900
+180,000
+162% +$11.2M 1.44% 16
2025
Q3 		$6.1M Sell
110,900
-39,100
-26% -$1.61M 0.62% 38
2025
Q2 		$4.96M Buy
+150,000
New +$5.22M 0.95% 33
2024
Q4 		– Sell
-52,300
Closed -$2.76M – 186
2024
Q3 		$2.76M Buy
+52,300
New +$2.92M 0.39% 65
2024
Q1 		– Sell
-603,500
Closed -$50.4M – 152
2023
Q4 		$50.4M Buy
603,500
+601,465
+29,556% +$21.8M 4.72% 2
2023
Q3 		$6M Buy
+2,035
New +$67.8K 0.72% 40
2021
Q1 		– Sell
-150,000
Closed -$3.12M – 310
2020
Q4 		$3.12M Sell
150,000
-1,021,600
-87% -$18.7M 0.14% 127
2020
Q3 		$25.4M Buy
+1,171,600
New +$27.4M 1.84% 10
2020
Q2 		– Sell
-500,000
Closed -$5.89M – 182
2020
Q1 		$5.89M Buy
+500,000
New +$6.38M 0.44% 56

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ikarian Capital's CYTK Position: Q2 2026 in Review

Ikarian Capital sold out of Cytokinetics (CYTK) in Q2 2026, closing a stake of 283,572 shares — an estimated $18.7M sold.

Ikarian Capital first reported a position in CYTK in Q3 2020 and held it in 15 quarters. The position peaked at $18.7M in Q1 2026. 483 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Ikarian Capital reported no remaining Cytokinetics position as of Q2 2026 after selling out during the quarter.
  • Ikarian Capital sold 283,572 Cytokinetics shares in Q2 2026, an estimated $18.7M.
  • Ikarian Capital first reported a position in Cytokinetics in Q3 2020 and held it in 15 quarters.
  • Ikarian Capital's Cytokinetics position peaked at $18.7M in Q1 2026.
  • 483 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.